News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Neogenix Oncology, Inc. Obtains Patent in Europe Relating to Its NEO-301 Antibody


5/12/2011 11:08:00 AM

Neogenix Oncology is pleased to announce that it will be granted a European Patent (“EP”) relating to its NEO-301 antibody (also known as 31.1), to take effect beginning September 23, 2011. The European Patent Office issued a “Decision to Grant” the company’s patent application, designated as EP Patent No. 02726672.5, on December 23, 2010. This patent will be in force until March 15, 2022.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES